Gamida Cell is a cell therapy company working to turn cells into therapeutics. Co. applies a proprietary expansion platform utilizing the properties of nicotinamide to allogeneic cell sources including umbilical cord blood-derived cells and natural killer (NK) cells to create cell therapy candidates. Co.'s primary product candidate, omidubicel, is a cell therapy for allogeneic hematopoietic stem cell transplant. Co.'s clinical stage NK cell therapy candidate, GDA-201, is in the Phase 1/2 clinical trial of GDA-201 for the treatment of follicular and diffuse large B-cell lymphomas. The GMDA average annual return since 2018 is shown above.
The Average Annual Return on the GMDA average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether GMDA average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the GMDA average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|